Elutia Past Earnings Performance

Past criteria checks 0/6

Elutia's earnings have been declining at an average annual rate of -27.9%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 16.3% per year.

Key information

-27.9%

Earnings growth rate

53.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-16.3%
Return on equityn/a
Net Margin-243.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Elutia Inc. (NASDAQ:ELUT) Held Back By Insufficient Growth Even After Shares Climb 26%

Nov 20
Elutia Inc. (NASDAQ:ELUT) Held Back By Insufficient Growth Even After Shares Climb 26%

Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Jun 28
Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Mar 10
News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Feb 21
Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Apr 17
Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Aziyo Biologics appoints Williams as Chief Scientific Officer

Aug 26

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aug 10

Revenue & Expenses Breakdown

How Elutia makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:ELUT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2425-60304
30 Jun 2425-70284
31 Mar 2425-49274
31 Dec 2325-41274
30 Sep 2325-32285
30 Jun 2325-35316
31 Mar 2319-38337
31 Dec 2224-36348
30 Sep 2228-39349
30 Jun 2234-373410
31 Mar 2246-283310
31 Dec 2147-25339
30 Sep 2149-21338
30 Jun 2149-23327
31 Mar 2146-26296
31 Dec 2043-25286
30 Sep 2042-23285
30 Jun 2042-16284
31 Mar 2043-13273
31 Dec 1943-12262
31 Dec 1839-12222

Quality Earnings: ELUT is currently unprofitable.

Growing Profit Margin: ELUT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ELUT is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.

Accelerating Growth: Unable to compare ELUT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ELUT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: ELUT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 14:22
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Elutia Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brandon FolkesCantor Fitzgerald & Co.
Ross OsbornCantor Fitzgerald & Co.
Frank TakkinenLake Street Capital Markets, LLC